SLC5A2 and cardiac hypertrophy: In HFD mice, SGLT2 inhibitors effectively reduce diastolic dysfunction, myocardial hypertrophy and fibrosis, mRNA for inflammatory and fibrosis markers as well as myocardial ROS production [164,165].